Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against Amicus Therapeutics, Inc. and Lead Plaintiff Deadline December 7, 2015

Dec 01, 2015, 10:00 ET from Bronstein, Gewirtz & Grossman, LLC

NEW YORK, Dec. 1, 2015 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court for the District of New Jersey on behalf of those who purchased shares of Amicus Therapeutics, Inc. ("Amicus" or the "Company") (NasdaqCM: FOLD), during the period between March 19, 2015 and October 1, 2015 inclusive. (the "Class Period").

The lawsuit alleges that the Company made false and/or misleading statements and/or failed to disclose that the United States Food and Drug Administration raised concerns about Amicus Therapeutics' forthcoming new drug application for migalastat during their September 15, 2015 meeting.

On October 2, 2015, Amicus announced that after meeting with FDA officials earlier in the week, the company does not anticipate being in a position to submit a new drug application (NDA) for migalastat, the company's Fabry disease treatment, by the end of the year. The FDA has requested further integration of existing clinical data across studies, which will require more time to complete.

Following this news, shares of Amicus Therapeutics fell $7.36 or over 53% to close at $6.39 on October 2, 2015.

No Class has yet been certified in the above action. If you wish to review a copy of the Complaint, to discuss this action, or have any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.  If you suffered a loss in Amicus you have until December 7, 2015 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com

 

SOURCE Bronstein, Gewirtz & Grossman, LLC



RELATED LINKS

http://www.bgandg.com